241 |
Investigation into the use of a novel respiratory monitor for gated radiotherapy of lung tumoursChow, Tat Ming January 2010 (has links)
No description available.
|
242 |
Development of quality standards for diagnostic imaging in GhanaOfori, Eric Kwasi January 2009 (has links)
No description available.
|
243 |
A Semiconductor Compton Camera InvestigationGrint, Alexander Newton January 2009 (has links)
No description available.
|
244 |
Monte Carlo modelling of small field dosimetry : non-ideal detectors, electronic disequilibrium and source occlusionScott, Alison Jane Dalgleish January 2009 (has links)
No description available.
|
245 |
Mechanistic simulation of normal-tissue damage in radiotherapyRutkowska, Eva Sofie January 2010 (has links)
No description available.
|
246 |
The relationship between RAF-1 protein level, radiosensitivity, and post-irradiation G2+M cell cycle accumulation in the context of P53 mutational statusJones, Mark January 2009 (has links)
No description available.
|
247 |
A quantitative assessment of the performance of a planar germanium detector for PET imagingOxley, David Christopher January 2010 (has links)
No description available.
|
248 |
A design study of the semiconductor sensor head for the ProSPECTus Compton CameraHarkness, Laura Joanne January 2010 (has links)
No description available.
|
249 |
The prediction of response to chemotherapy in patients with oesophago-gastric cencer using positron emission tomographySuttie, Stuart Alistair January 2008 (has links)
Conventional anatomical imaging relies on changes in tumour volume, which do not become appreciable until late. Positron Emission Tomography (PET, using metabolically active tracers) offers an alternative, as metabolic changes occur prior to volume reduction. <sup>18</sup>FDG PET, monitoring glucose uptake in cells, has been used with some success. <sup>11</sup>C-Choline PET, monitoring cellular proliferation, may be more accurate. 18 patients with tumours at or around the gastro-oesophageal junction, underwent PET imaging with both <sup>18</sup>FDG and <sup>11</sup>C-Choline prior to and at day seven and fourteen into the first cycle of the chemotherapy (neo-adjuvant and palliative). Tumour uptake of each tracer was determined using SUV and Patlak analysis. The initial tumour tracer uptake and the change in uptake over time were correlated with tumour regression grade, pathological response, survival and cellular ki-67 expression. All 18 primary tumours were visualised with <sup>18</sup>FDG PET in contrast to 16/18 with <sup>11</sup>C-Choline. Four out of nine (44%) patients had a pathological response following neo-adjuvant chemotherapy. Pathological responders had a median survival of 16.1 months in comparison to non responders of 19.0 months (<i>p</i>=0.978). At day 14, tumours with less than median reduction in <sup>11</sup>C-Choline uptake (Patlak) had a median survival of 15.4 months compared to 10.9 months for those with a greater than median reduction (<i>p</i>=0.069). Initial and change in <sup>11</sup>C-Choline or <sup>18</sup>FDG uptake did not correlate with ki-67 tumour count. Tumours with less than the median reduction in ki-67 count following chemotherapy had a median survival of 12.8 months compared to those with a greater than median reduction 14.7 months (<i>p</i>=0.319). Although limited by small numbers, the change in <sup>11</sup>C-Choline uptake at day fourteen into the first chemotherapy cycle, best predicts survival for tumours at or around the gastro-oesophageal junction. <sup>11</sup>C-Choline uptake did not directly correlate with ki-67 expression.
|
250 |
Digital computer processing of radioisotope scansBarber, D. C. January 1972 (has links)
No description available.
|
Page generated in 0.0182 seconds